Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of OGEN stock opened at $1.03 on Friday. The stock has a 50-day moving average price of $1.60. The firm has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.12 and a beta of 0.50. Oragenics has a 12 month low of $0.97 and a 12 month high of $7.74.

Oragenics (NYSE:OGEN) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.70) EPS for the quarter.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent quarter. 18.71% of the stock is owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.